Capital Research Global Investors Gilead Sciences, Inc. Transaction History
Capital Research Global Investors
- $440 Billion
- Q1 2025
A detailed history of Capital Research Global Investors transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Capital Research Global Investors holds 54,610,370 shares of GILD stock, worth $5.94 Billion. This represents 1.39% of its overall portfolio holdings.
Number of Shares
54,610,370
Previous 57,946,228
5.76%
Holding current value
$5.94 Billion
Previous $5.35 Billion
14.32%
% of portfolio
1.39%
Previous 1.15%
Shares
31 transactions
Others Institutions Holding GILD
# of Institutions
2,305Shares Held
998MCall Options Held
9.62MPut Options Held
10M-
Black Rock Inc. New York, NY121MShares$13.1 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA117MShares$12.8 Billion0.25% of portfolio
-
State Street Corp Boston, MA59.5MShares$6.48 Billion0.28% of portfolio
-
Capital World Investors Los Angeles, CA53.5MShares$5.83 Billion1.01% of portfolio
-
Dodge & Cox San Francisco, CA32.7MShares$3.56 Billion2.24% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $136B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...